Is it wise_老虎社区_美港股上老虎

2021-12-28

Is it wise to invest in low cap non profitable growth stock in 2022 with tapering and interest hike? Seriously, not for me. [Surprised]

Buy and Hold This Unstoppable Growth Stock for the Next Decade

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696824062,"tweetId":"696824062","gmtCreate":1640667189916,"gmtModify":1640667190330,"author":{"id":3560153673056412,"idStr":"3560153673056412","authorId":3560153673056412,"authorIdStr":"3560153673056412","name":"JPHC","avatar":"https://static.tigerbbs.com/983066cca30c768ccae9fa351386fdfe","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":32,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Is it wise to invest in low cap non profitable growth stock in 2022 with tapering and interest hike? Seriously,&nbsp;not for me.&nbsp;<span>[Surprised]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p>Is it wise to invest in low cap non profitable growth stock in 2022 with tapering and interest hike? Seriously,&nbsp;not for me.&nbsp;<span>[Surprised]&nbsp;</span></p></body></html>","text":"Is it wise to invest in low cap non profitable growth stock in 2022 with tapering and interest hike? Seriously, not for me. [Surprised]","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696824062","repostId":2194770109,"repostType":4,"repost":{"id":"2194770109","pubTimestamp":1640663220,"share":"https://www.laohu8.com/m/news/2194770109?lang=&edition=full","pubTime":"2021-12-28 11:47","market":"us","language":"en","title":"Buy and Hold This Unstoppable Growth Stock for the Next Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=2194770109","media":"Motley Fool","summary":"When it comes to raking in recurring revenue, this company is a king.","content":"<p>Getting medical care is expensive regardless of the patient's species. People need health insurance for themselves, so why not for Fido?</p>\n<p>And that's the pitch for <b><a href=\"https://laohu8.com/S/TRUP\">Trupanion</a></b>&nbsp;(NASDAQ:TRUP), a health insurance company made just for pets. For growth investors who are looking for a stock to hold throughout its galloping ascent, Trupanion has a lot to offer. Let's analyze why.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F658285%2Fvet-holds-dog.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>This stock is going places</h2>\n<p>The key factor in Trupanion's future prospects is that its business model is highly repeatable.&nbsp;As with health insurance for humans, subscribers pay a monthly fee in exchange for coverage that reduces the out-of-pocket cost of veterinary care. After rendering care, veterinarians then bill the insurer for reimbursement for their costs. When everything goes according to plan, the company makes money by betting that, on average, pets will be happier and healthier far more frequently than they are sick or injured.</p>\n<p>In more quantitative terms, 98.7% of enrolled pets remain enrolled each month, and the company estimates that it makes $63.30 in revenue and $8.29 in cash per month per pet. So, each additional subscriber means a significant amount of revenue down the line -- and as of the Q3 earnings report, the total number of enrolled pets has increased by 37% compared to the third quarter in 2020.</p>\n<p>Over the last three years, quarterly revenue has grown by nearly 120%, and with the ongoing rapid subscriber growth, it's easy to see how the good times could keep rolling. That's especially true when considering that the market for pet insurance in the U.S. is still largely untapped, with management citing research suggesting a penetration rate of only 1%.</p>\n<p>In other words, there's more smooth sailing to come, since there aren't any powerful competitors anywhere on the horizon. And, with the online pet goods company <b>Chewy </b>announcing earlier this month that it would be teaming up with Trupanion to offer pet insurance to its customers. This is yet another growth driver on the radar for next year and beyond.</p>\n<h2>There aren't many headwinds to worry about either</h2>\n<p>In keeping with the success of its ongoing expansion into the pet insurance market, Trupanion doesn't have many issues that might give investors pause.</p>\n<p>Its total expenses as a percentage of quarterly revenue aren't rising sharply over time, and it is currently debtless. While consistently posting a profit remains a challenge, the company had some free cash flow (FCF) in 2019 and 2020 anyway. Although it is unprofitable, its net margin is within 5% of being positive, so it's entirely feasible for it to keep growing rapidly and worry about increasing efficiency once the market starts to get crowded.</p>\n<p>The largest risk to shareholders may be dilution. Last year, Trupanion raised $192.3 million by issuing new stock, which was far more than it issued in the previous five years. Still, new stock hasn't been issued in 2021, and it might not be anytime soon. With more than $221.5 million in the bank, there's a long runway to figure out how to provide profitable coverage.</p>\n<p>In a nutshell, this is a solid business that's very much in the window of opportunity for newcomers to invest. As a bonus, most investors probably don't have direct exposure to the pet health insurance market in their portfolios, so Trupanion could also be considered a great way to diversify.&nbsp;At the end of the day, buying this stock is a bet that people will continue to love their pets and look out for their pets' health. To me, that's a slam dunk.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy and Hold This Unstoppable Growth Stock for the Next Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy and Hold This Unstoppable Growth Stock for the Next Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 11:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/27/buy-and-hold-this-unstoppable-growth-stock-for-the/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Getting medical care is expensive regardless of the patient's species. People need health insurance for themselves, so why not for Fido?\nAnd that's the pitch for Trupanion (NASDAQ:TRUP), a health ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/27/buy-and-hold-this-unstoppable-growth-stock-for-the/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4162":"人寿与健康保险","TRUP":"Trupanion","BK4211":"区域性银行"},"source_url":"https://www.fool.com/investing/2021/12/27/buy-and-hold-this-unstoppable-growth-stock-for-the/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194770109","content_text":"Getting medical care is expensive regardless of the patient's species. People need health insurance for themselves, so why not for Fido?\nAnd that's the pitch for Trupanion (NASDAQ:TRUP), a health insurance company made just for pets. For growth investors who are looking for a stock to hold throughout its galloping ascent, Trupanion has a lot to offer. Let's analyze why.\nImage source: Getty Images.\nThis stock is going places\nThe key factor in Trupanion's future prospects is that its business model is highly repeatable. As with health insurance for humans, subscribers pay a monthly fee in exchange for coverage that reduces the out-of-pocket cost of veterinary care. After rendering care, veterinarians then bill the insurer for reimbursement for their costs. When everything goes according to plan, the company makes money by betting that, on average, pets will be happier and healthier far more frequently than they are sick or injured.\nIn more quantitative terms, 98.7% of enrolled pets remain enrolled each month, and the company estimates that it makes $63.30 in revenue and $8.29 in cash per month per pet. So, each additional subscriber means a significant amount of revenue down the line -- and as of the Q3 earnings report, the total number of enrolled pets has increased by 37% compared to the third quarter in 2020.\nOver the last three years, quarterly revenue has grown by nearly 120%, and with the ongoing rapid subscriber growth, it's easy to see how the good times could keep rolling. That's especially true when considering that the market for pet insurance in the U.S. is still largely untapped, with management citing research suggesting a penetration rate of only 1%.\nIn other words, there's more smooth sailing to come, since there aren't any powerful competitors anywhere on the horizon. And, with the online pet goods company Chewy announcing earlier this month that it would be teaming up with Trupanion to offer pet insurance to its customers. This is yet another growth driver on the radar for next year and beyond.\nThere aren't many headwinds to worry about either\nIn keeping with the success of its ongoing expansion into the pet insurance market, Trupanion doesn't have many issues that might give investors pause.\nIts total expenses as a percentage of quarterly revenue aren't rising sharply over time, and it is currently debtless. While consistently posting a profit remains a challenge, the company had some free cash flow (FCF) in 2019 and 2020 anyway. Although it is unprofitable, its net margin is within 5% of being positive, so it's entirely feasible for it to keep growing rapidly and worry about increasing efficiency once the market starts to get crowded.\nThe largest risk to shareholders may be dilution. Last year, Trupanion raised $192.3 million by issuing new stock, which was far more than it issued in the previous five years. Still, new stock hasn't been issued in 2021, and it might not be anytime soon. With more than $221.5 million in the bank, there's a long runway to figure out how to provide profitable coverage.\nIn a nutshell, this is a solid business that's very much in the window of opportunity for newcomers to invest. As a bonus, most investors probably don't have direct exposure to the pet health insurance market in their portfolios, so Trupanion could also be considered a great way to diversify. At the end of the day, buying this stock is a bet that people will continue to love their pets and look out for their pets' health. To me, that's a slam dunk.","news_type":1},"isVote":1,"tweetType":1,"viewCount":823,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":112,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696824062"}